CLCarl Van Laer

Carl Van Laer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carl Van Laer has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Case of Necrotizing Sialometaplasia After Laryngeal Mask Airway Ventilation

    by Giada Bilotta, Karl Hendrickx, Steven Mariën, Annelies Verbruggen, Carl Van Laer

    Necrotizing sialometaplasia (NS) is a rare, benign, self-limiting inflammatory disease of the salivary glands that can clinically and histopathologically mimic malignancy. It most commonly presents as a painful ulcer of the hard palate. The lesion is believed to be the result of ischemia of the salivary gland lobules with subsequent repair and metaplasia. Necrotizing sialometaplasia heals spontaneously and requires no treatment. This report demonstrates a case of NS in a 33-year-old female patient who presented with a bilateral, painful swelling of the hard palate that evolved into an ulcer a few days after surgery with laryngeal mask airway ventilation. Hyperbaric oxygen therapy was attempted to enhance healing. Cite this article as: Bilotta G, Hendrickx K, Mariën S, Verbruggen A, Van Laer C. A case of necrotizing sialometaplasia after laryngeal mask airway ventilation. B-ENT. 2024;20(4):272-275.

  • A patient with a severe glottic stenosis and saddle nose

    by Vito Sabato, Olivier M Vanderveken, Tim Van Den Wyngaert, Carl Van Laer, Didier Ebo

    We present the case of a 39-year-old man with a severe glottis stenosis. The saddle nose, images of laryngotracheal stenosis and the (FDG) positron-emission tomography/computed tomography lead to a final diagnosis of relapsing polychondritis. In the patient a coexistent myelodysplastic syndrome was diagnosed. Moreover, the elevated total IgG4 exceeding 135 ml/dl requested additional immunochemistry for detection of IgG4-bearing plasma cells in the biopsies. The patient underwent an allogenic stem cell transplantation and died on day 40 after the transplantation because of an acute steroid-resistent graft vs host.


  • Open Access

    Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?

    by Gwen Van Nuffelen, Leen Van Den Steen, Olivier Vanderveken, Pol Specenier, Carl Van Laer, Diane Van Rompaey, Cindy Guns, Steven Mariën, Marc Peeters, Paul Van de Heyning, et al.

    Reduced tongue strength is an important factor contributing to early and late dysphagia in head and neck cancer patients previously treated with chemoradiotherapy. The evidence is growing that tongue strengthening exercises can improve tongue strength and swallowing function in both healthy and dysphagic subjects. However, little is known about the impact of specific features of an exercise protocol for tongue strength on the actual outcome (strength or swallowing function). Previous research originating in the fields of sports medicine and physical rehabilitation shows that the degree of exercise load is an influential factor for increasing muscle strength in the limb skeletal muscles. Since the tongue is considered a muscular hydrostat, it remains to be proven whether the same concepts will apply. This ongoing randomized controlled trial in chemoradiotherapy-treated patients with head and neck cancer investigates the effect of three tongue strengthening exercise protocols, with different degrees of exercise load, on tongue strength and swallowing. At enrollment, 51 patients whose dysphagia is primarily related to reduced tongue strength are randomly assigned to a training schedule of 60, 80, or 100 % of their maximal tongue strength. Patients are treated three times a week for 8 weeks, executing 120 repetitions of the assigned exercise once per training day. Exercise load is progressively adjusted every 2 weeks. Patients are evaluated before, during and after treatment by means of tongue strength measurements, fiber-optic endoscopic evaluation of swallowing and quality-of-life questionnaires. This randomized controlled trial is the first to systematically investigate the effect of different exercise loads in tongue strengthening exercise protocols. The results will allow the development of more efficacious protocols. Current Controlled Trials ISRCTN14447678 .


    • 1 December 2009
      • Vol. 29  (12) , 5137-42

    Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

    by Pol M Specenier, Jan Van Den Brande, Dirk Schrijvers, Manon T Huizing, Sevilay Altintas, Joke Dyck, Danielle Van Den Weyngaert, Carl Van Laer, Jan B Vermorken

    Docetaxel, ifosfamide and cisplatin have all shown activity in squamous cell carcinoma of the head and neck (SCCHN). The optimal combination of the three drugs is, however, unknown. Considering the favorable results of taxane-containing triplets as induction chemotherapy in locally advanced (LA) SCCHN, DIP (docetaxel, ifosfamide, cisplatin) was studied in this setting as part of a phase I dose- and sequence-exploring study. D (60 or 75 mg/m(2)) was given by 60-min infusion on day 1, I (1000 mg/m(2)/day), with mesna until 12 hours after I, by 24-h infusion days 1-5, and P (50 or 75 mg/m(2)) by 24-h infusion on days 1 or 5. The cycles were repeated every 21 days. Toxicities according to the National Cancer Institute Common Toxicity Criteria version 2 (NCI-CTC2) were evaluated weekly and response was evaluated every 2 cycles according to the World Health Organization (WHO) criteria. Thereafter, radiotherapy (RT, cumulative dose 70 Gy) or chemoradiation (CRT), both with conventional fractionation, were planned. Twenty-two patients (18 male, 4 female; age 41-66 years, performance status 0-1, 2 T4N0, 3 T3N2, 11 T4N2, 3 T unknown N3, 1 T1N3 and 2 T4N3) received a median of 4 DIP cycles (range 1-5). Grade 4 neutropenia occurred in 18 patients, grade 3 and 4 thrombocytopenia in 5 and 1 patients, respectively, and grade 3 anemia in 5 patients. Gastrointestinal and mucosal toxicities were generally mild/moderate. Vascular complications (probably not DIP-related) precluded local treatment in two patients. Moreover, one patient died on day 13 of the first DIP (neutropenic sepsis and myocardial infarction). The remaining patients received RT (n=2) or CRT (n=17; 16 of these with gemcitabine). The response to 2 x DIP was 95% (1 complete response, 19 partial responses, 1 stable disease); the complete response rate increased to 42% after 4 x DIP. No dose or sequence effect was evident. The minimum follow-up of the surviving patients was 51 months, with median relapse-free survival of 13.8 months and median overall survival of 18.8 months. Only four patients relapsed at distant sites. DIP is highly active in previously untreated LA SCCHN, however, toxicity of DIP in this population is substantial.


  • Open Access

    A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

    by Pol M Specenier, Joost Weyler, Carl Van Laer, Danielle Van Den Weyngaert, Jan Van Den Brande, Manon T Huizing, Sevilay Altintas, Jan B Vermorken

    Concomitant chemotherapy and radiotherapy (chemoradiation; CRT) is the standard treatment for locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). CRT improves local control and overall survival (OS) when compared to radiotherapy (RT) alone. Induction chemotherapy (IC) reduces the risk of distant metastases (DM) and improves OS by 5% with the use of cisplatin/infusional 5 fluorouracil (PF) in meta-analysis. Adding a taxane to PF in the IC regimen confers a better outcome. Sequential treatment (ST) of IC followed by CRT is therefore under active investigation in multiple phase III trials.